Key Drivers
- Very strong liquidity
- No revenue/losses
- Major share dilution
AIAI Summary
Reframed from a cash‑survival story to a well‑capitalized clinical‑stage bet, LBRX's value now depends squarely on LB‑102 clinical execution (topline ~1Q‑2028)—monitor enrollment/interim readouts closely and avoid buying ahead of definitive Phase‑2/3 data given material dilution risk if trials or partnering falter.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very strong liquidity
- •No revenue/losses
- •Major share dilution
LBRX: extremely strong cash position and minimal debt after a large financing, but no revenue, ongoing operating losses and negative free cash flow, and substantial share dilution that raises investor risk.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Support cluster
- •Resistance ceiling
Over the last month LBRX has slipped into a short-term downtrend trading below its last month SMA (~$24.34) after a mid‑March spike to $26.46, finding near-term support around $23.5–$24.0 while resistance sits near $25.1–$26.46.
Spike to $26.46 on 2026-03-16 followed by a rapid pullback indicating short-term volatility
Sentiment & News
Key News Insights:
- •Lock-up expiry
- •Board appointment
- •52‑week high
LB Pharmaceuticals' coordinated investor engagement and board appointment ahead of the lock-up expiry preceded analyst activity and a mid‑March 52‑week high.
The governance and IR push likely boosted market confidence and liquidity, contributing to short‑term upward pressure on LBRX shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings